EUCTR2006-000674-73-ES进行中（未招募）不适用
ESTUDIO ALEATORIZADO, A DOBLE CIEGO, CONTROLADO CON PLACEBO, DE TRES BRAZOS, GRUPOS PARALELOS, MULTICÉNTRICO Y MULTINACIONAL SOBRE LA SEGURIDAD Y EFICACIA DE 300 MG Y 900 MG DE ABETIMUS SÓDICO EN PACIENTES CON LUPUS ERITEMATOSO SISTÉMICO (LES) CON ANTECEDENTES DE NEFROPATÍA
a Jolla Pharmaceutical Company0 个研究点目标入组 730 人开始时间: 2007年12月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 730
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient must meet all the following criteria in order to participate in
- •this trial:
- •2.1.1 Males or females between 12 and 70 years old, inclusive.
- •2.1.2 Female patients must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment in the study. Female patients of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate of less than 1% per year, when used consistently and correctly, for example oral contraceptives, contraceptive patch, implants,
- •injectables, some intrauterine contraceptive devices [IUDs], or sexual abstinence) during the entire duration of the study. Males enrolled in the trial must have no plans to father a child during the course of the trial and agree to use adequate birth control methods.
- •2.1.3. Diagnosis of SLE for purposes of this trial utilize the 1996 Revised Criteria for the Classification of SLE as defined by the American College of Rheumatology (ACR) where a diagnosis of SLE is established when = 4 of the 11 criteria are met (refer to Section 8.2 of protocol).
- •2.1.4 At least one documented episode of active SLE renal disease within 4 years prior to randomization at study Visit 3 as defined by at least one of the following:
- •- A renal biopsy showing active lesions of SLE, Morphologic Classification of Lupus Nephritis defined by the World Health Organization (WHO) Class III, IV or V (refer to Section 8.3 of protocol)
- •- Increase in serum creatinine:
- •by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL
- •by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL
- •AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.
- •Patients with hereditary C4 deficiency cannot qualify on the C4 or CH50 criterion alone.
- •-Increase in proteinuria:
- •to greater than 1000 mg/24 hr if the previous value was < 200 mg/24 hr
- •to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr
- •to greater than 2 times the previous value if that value was > 1000 mg/24 hr
- •- Use of cyclophosphamide to treat lupus nephritis that is documented in clinical or hospital records.
- •2.1.5 Elevated anti-dsDNA antibody concentration at pre-screening Visit 0 (= 10 IU/mL) as measured by the Farr assay at the regional central laboratory.
- •2.1.6. Ability to communicate meaningfully with the investigational staff, competence to give written informed consent, and ability to comply with the entire study procedure.
- •2.1.7 Duly executed, written, informed consent obtained from the patient, next of kin, or other legal representative.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following will exclude a patient from this trial:
- •2.2.1 Active SLE renal disease in the 3 months prior to Visit 3 as evidenced by:
- •- Increase in serum creatinine:
- •by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL
- •by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL
- •AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.
- •- Reproducible increase in proteinuria:
- •to greater than 1000 mg/24 hr if the previous value was < 200 mg/24 hr
- •to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr
- •to greater than 2 times the previous value if that value was > 1000 mg/24 hr
- •2.2.2 An increase in the anti-dsDNA antibody concentration of more than 50% with an incremental increase of at least 50 units in anti-dsDNA antibody concentration by Farr assay between the samples taken at Visit 0 and Visit 1 during the screening period.
- •2.2.3 Use of the following therapeutics:
- •- Prednisone > 20 mg/day within 1 month prior to Visit 1
- •- Any use of the following therapies or therapeutics within 2 months prior to randomization or 1 month prior to Visit 1:
- •alkylating agents (e.g., cyclophosphamide)
- •TNF inhibitors (e.g., etanercept, infliximab)
- •cyclosporine
- •plasmapheresis
- •intravenous immunoglobulin
- •prosorba column
- •- Any use of mycophenolate mofetil that exceeds 1000 mg/day 1 month prior to Visit 1
- •- Any use of azathioprine that exceeds 100 mg/day within 1 month prior to Visit 1
- •- Any use of methotrexate that exceeds 10 mg/week within 1 month prior to Visit 1
- •- Any use of leflunomide that exceeds 10 mg/day within 1 month prior to Visit 1
- •- Any use of rituximab within 5 months prior to Visit 1
- •- Previous or concurrent medications and other therapies or devices that in the judgment of the Investigator are likely to confound the evaluation of the safety or efficacy of abetimus sodium. Examples include:
- •- immunosuppressants or immunomodulatory drugs other than those therapies specifically noted above to include new immunomodulatory agents that may become commercially available during the course of the study
- •- drugs that have the potential to induce SLE (e.g., isoniazid, phenytoin, hydralazine, procainamide, etc.)
- •- radiation therapy within 1 year.
- •- If the Investigator has any question concerning a particular medication, he/she should discuss this with the Medical Monitor prior to enrollment.
- •- Patient has received any investigational new drug or device within 30 days prior to screening or 5 half-lives of the agent (whichever is longer), or any investigational new drug with a long-term effect.
- •- Prior participation in study LJP 394-90-14
- •2.2.4 Exclusionary laboratory values:
- •leukocyte count < 2,000 cells/mm3
- •platelet count < 50,000 cells/mm3
- •hemoglobin < 8.5 gm/dL
- •serum hepatic transaminases = 3X the upper limit of normal
- •serum creatinine > 3.5 mg/dL within the 2 months prior to randomization
- •2.2.5 Malignant disease or immunodeficiency syndrome within 5 years, excepting patients with basal cell or squamous cell carcinoma of the skin with complete excision and clean borders.
- •2.2.6 Evidence of current abuse of drugs or alcohol.
- •2.2.7 History of poor procedural compliance in previous investigational studies.
- •2.2.8 History of serious cardiac disease or functional classification New York Heart Association Class III or IV.
- •2.2.9 Patient has previously undergone organ transplantation.
- •2.2.10 Other medical c
研究者
相似试验
进行中（未招募）
1 期
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, CON GRUPOS PARALELOS, MULTICÉNTRICO, PARA INVESTIGAR LA SEGURIDAD Y LA EFICACIA DE CP 690,550 EN SUJETOS CON COLITIS ULCEROSA DE MODERADA A GRAVEA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITISCP 690,550 es un fármaco en desarrollo para el tratamiento de los pacientes con colitis ulcerosa de moderada a grave.CP-690,550 is being developed for the treatment of patients with moderate-to-severe ulcerative colitis.MedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2008-004564-40-ESPfizer S.A200
进行中（未招募）
不适用
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO DE [S,S]-REBOXETINA EN PACIENTES CON NEUROPATIA PERIFERICA DOLOROSA CRÓNICA” Y SUPLEMENTO DE DETERMINACIÓN DEL PERFIL MOLECULARA RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHYPACIENTES CON NEUROPATÍA DIABÉTICA PERIFÉRICA DOLOROSA CRÓNICAMedDRA version: 9.1Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathyEUCTR2007-004733-41-ESPfizer. S.A450
进行中（未招募）
不适用
ESTUDIO ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LEGALON SIL EN EL TRATAMIENTO DE LA RECURRENCIA DE VHC EN EL INJERTO DE PACIENTES SOMETIDOS A UN TRASPLANTE ORTOTÓPICO DE HÍGADO / A randomized, double-blind, placebo controlled, study to investigate the efficacy and safety of Legalon SIL for the treatment of HCV recurrence of the graft in orthotopic liver transplant patientsEUCTR2010-019505-42-ESRottapharm SpA
进行中（未招募）
不适用
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO POR PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL USO PROFILÁCTICO DE MARIBAVIR PARA LA PREVENCIÓN DE ENFERMEDAD DE CITOMEGALOVIRUS EN RECEPTORES DE TRASPLANTES DE CÉLULAS MADRE ALOGÉNICOSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS.so profiláctico de maribavir para la prevención de enfermedad de citomegalovirus en receptores de trasplantes de células madre alogénicosMedDRA version: 8.1Level: LLTClassification code 10009701Term: CMVEUCTR2006-005692-18-ESViroPharma Incorporated613
进行中（未招募）
1 期
ESTUDIO DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA FARMACODINAMIA DE AT1001 EN PACIENTES CON ENFERMEDAD DE FABRY Y MUTACIONES EN GLA SENSIBLES A AT1001.A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS.Enfermedad de Fabry.Fabry Disease.MedDRA version: 12.0Level: LLTClassification code 10016016Term: Fabry's diseaseEUCTR2009-013459-31-ESAmicus Therapeutics, Inc.180